Evaluating markers and imaging for predicting outcomes in pituitary tumors
Predictive Value of Serum and Tissue Molecular Markers and Imaging Features in the Invasiveness and Prognosis of Pituitary Neuroendocrine Tumors
This study is trying to find out if certain blood tests and scans can help predict how aggressive pituitary tumors will be and how well patients will do over time.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 300 (estimated) |
| Ages | 18 Years to 70 Years |
| Sex | All |
| Sponsor | Sun Yat-sen University Academic / other |
| Drugs / interventions | chemotherapy, radiation |
| Locations | 1 site (Guangzhou, Guangdong) |
| Trial ID | NCT06015802 on ClinicalTrials.gov |
What this trial studies
This observational study aims to identify serum and tissue molecular markers, as well as imaging features, that can predict the invasiveness and prognosis of pituitary neuroendocrine tumors. Given the variability in clinical manifestations and the resistance of some tumors to conventional treatments, the study will monitor changes in these biomarkers and imaging characteristics throughout the disease course and treatment. By doing so, it seeks to improve early prediction of tumor proliferation, progression, and recurrence risk following medical or surgical interventions.
Who should consider this trial
Good fit: Ideal candidates include patients diagnosed with pituitary neuroendocrine tumors, specifically pituitary adenomas confirmed by clinical imaging.
Not a fit: Patients with pituitary carcinoma, those who have received prior radiation or chemotherapy, or individuals with certain genetic syndromes will not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to improved prediction and management of pituitary neuroendocrine tumors, enhancing patient outcomes.
How similar studies have performed: While there may be studies exploring similar biomarkers, this specific approach to predicting invasiveness and prognosis in pituitary neuroendocrine tumors is relatively novel.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: Patients with pituitary neuroendocrine tumors: pituitary adenoma was diagnosed by clinical imaging, with or without pituitary hormone secretion function was confirmed by pituitary hormone detection. Exclusion Criteria: 1. Previous pathological specimen suggested pituitary carcinoma. 2. always have received radiation and chemotherapy or immune and targeted therapy of the patients. 3. with known genetic syndrome can cause excessive secretion of hormones (such as Carney syndrome, McCune - Albright syndrome, multiple endocrine neoplasia type 1, acute interstitial pneumonia) patients. 4. there are ectopic neuroendocrine tumor patients. 5. within one month before the screening for major surgery, or within 3 months before screening for patients with sphenoid pituitary surgery. 6. crisis of gland function (the pituitary gland, thyroid crisis, adrenal crisis). 7. peripheral glands or other solid tumors in patients with severe disease or blood system. 8. serious organ damage such as heart, kidney, liver, etc. 9. with severe mental or nervous system disease. 10. serious high blood glucose or poorly controlled hypertension or emergency patients.
Where this trial is running
Guangzhou, Guangdong
- endocrinology department of the first affiliated hospital of Sun Yat-sen University — Guangzhou, Guangdong, China (Recruiting)
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.